Objectives: We investigated why, despite its beneficial effect on the CD4 cell count, IL-2 therapy had no clinical benefit as shown in the ESPRIT and SILCAAT trials. We focused on subgroups of patients defined according to CD4 cell counts at baseline and over time to assess the threshold above which IL-2 therapy was no longer beneficial in a large cohort of HIV-1 infected patients.
Introduction
Combined antiretroviral therapy (cART) controls HIV replication, promotes immune recovery and reduces morbidity and mortality. 1, 2 However, immune recovery is only partial and the virus cannot yet be eradicated, 3 meaning that treatment must be given for life. Long-term cART is associated with adverse effects and the emergence of drug-resistant variants. Furthermore, the CD4 cell count sometimes fails to recover despite appropriate cART. 4 Adjuvant interleukin-2 (IL-2) immunotherapy has been used in an attempt to bolster immunological reconstitution in this setting. Indeed, IL-2 co-administration amplifies cART-induced CD4 cell recovery, 5 -9 notably by prolonging CD4 cell survival and decreased turnover and cell death. 10, 11 It has been suggested 12 that IL-2 therapy may be most beneficial in patients with weak immunological responses to cART. 6, 7, 13 Concerns have been raised regarding the potential induction of lymphomas by IL-2 therapy but no such phenomenon has been observed. 14 A clinical benefit of IL-2 therapy has been noted in some small studies, 15, 16 but no improvement in clinical outcome was seen in two large randomized trials, SILCAAT and ESPRIT (enrolment of patients with , or ≥300 CD4 cells/mm 3 respectively), despite a significant increase in CD4 T cell count. 17, 18 These results raise questions about the functionality of CD4 T cells and/or whether the potential benefit of IL-2 could be counterbalanced by toxic effects. For example, precise analyses revealed that patients from the ESPRIT trial, but not the SILCAAT study, who experienced higher CD4 Tcell increases developed more grade 4 clinical events than control patients. 18 However, these studies were not designed to identify subgroups of patients who might benefit from IL-2 therapy.
Here we investigated whether the CD4 cell count level at initiation of IL-2 could influence the clinical benefit, as an explanation of why the CD4 cell count increment has not translated into a clear clinical benefit in the SILCAAT and ESPRIT trials. We focused on changes in CD4 cell count and the threshold above which IL-2 therapy was no longer beneficial.
Methods

Study population
The French Hospital Database on HIV (ANRS CO4, FHDH) is a large prospective cohort of HIV-infected patients created in 1989 and involving 62 hospitals throughout France. 19 Enrolment is ongoing. The only inclusion criteria are documented HIV-1 or HIV-2 infection and written informed consent. Demographic, clinical and biological data are collected prospectively on standardized forms by trained research assistants using medical data software. Clinical events are recorded, along with treatments, prophylaxis, deaths and causes of death, as noted in the medical records. A follow-up form is completed at each visit or hospital admission for an HIV-related clinical event or a new treatment prescription, or at least every 6 months.
By 31 December 2005, data on 106277 HIV-infected patients with a median follow-up of 49 months had been collected in the database. The database has been approved by the French computer watchdog commission (CNIL) according to the French legislation at the time.
Patients
The study was restricted to the modern cART era. Patients over 15 years of age were eligible for this analysis if they had at least two FHDH visits between 1 January 1998 and 31 December 2005, and if at least one CD4 cell count was available.
Patients who received at least one IL-2 injection were enrolled in the IL-2-treated group (exposed patients) at the date of their first IL-2 injection, which defined the baseline. Patients who received no IL-2 injections composed the IL-2-untreated group (unexposed patients). They were matched with the exposed patients with respect to the baseline date (+3 months), sex, age, the CD4 cell count and the plasma HIV-1 RNA level at baseline. In order to achieve adequate statistical power, we included up to 30 unexposed patients who met the matching criteria and who were randomly selected, with incidence density sampling, 20 for each exposed patient. Specifically, for each exposed patient sampling was done without replacement from the pool of unexposed patients. Randomization was performed using the RAND function of the SAS software package. Patients in the IL-2-treated group were not included in the IL-2-untreated group prior to IL-2 initiation.
Endpoint definition
A composite endpoint for clinical progression was used, defined as the occurrence of either a new AIDS-defining event (ADE; excluding recurrences) or death. ADEs are recorded in the database by using the International Classification of Diseases definitions version 10. 21 For this analysis, we considered the 23 ADEs corresponding to the clinical definitions of the 1993 CDC revised AIDS case definition. 22 Incident events were eligible for analysis if they occurred between the day after study entry and the end of follow-up, the latter being defined as the date of the first event (last follow-up visit, ADE, death or 31 December 2005, whichever occurred first). Death events which occurred less than 6 months after the last follow-up visit and were recorded in the database were included in analyses.
Statistical analysis
We used linear interpolation to fill in missing CD4 cell counts and plasma HIV-1 RNA levels between two recorded values. When follow-up was ongoing, the last recorded CD4 cell count and plasma HIV-1 RNA value were carried forward by 2 months. At the date of the event, if no CD4 cell count and plasma HIV-1 RNA values were available, the last recorded values were carried forward by 6 months. Otherwise, the event was censored.
Changes in the CD4 cell count between baseline and the end of the first year were compared between the two groups by using the MannWhitney test.
Multivariable Cox proportional hazards models were used to study the impact of IL-2 therapy on the risk of new ADEs or death according to the baseline CD4 cell count (,50, 50 to ,100, 100 to ,200, 200 to ,350 and ≥350 cells/mm 3 ). Hazard ratios (HRs) and their 95% confidence intervals (CIs) were also calculated. Sex, age (15 to ,40, 40 to ,50, 50 to ,60 and ≥60 years), plasma HIV-1 RNA (,500, 500 to ,30000 and ≥30 000 copies/mL), HIV-1 transmission group (intravenous drug users versus others), AIDS status (clinical criteria of the 1993 European revised case definition), 23 antiretroviral (ARV) treatment status (ARV naive; ARV experienced, but no current ARV therapy; non-cART ARV therapy; and cART) and primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmosis were included in the models, as they are known potential confounders in analyses of clinical progression. Combined ART was defined as a combination of three or more ARV drugs, or two ritonavir-boosted protease inhibitors, or one ritonavir-boosted protease inhibitor plus one non-nucleoside analogue reverse transcriptase inhibitor. Ritonavir was not included in the protease inhibitor count when used as a booster.
Based on the Cox model results, we further studied the relationship between IL-2 therapy and the incidence of ADE or death in the population with CD4 cell counts below 200 cells/mm 3 at baseline in order to determine the level up to which the IL-2 therapy-associated increase in CD4 cell count could be beneficial. Each patient's follow-up period was divided into consecutive 1 month periods. We used Poisson regression models stratified on updated CD4 cell counts (,100, 100 to ,350 and ≥350 cells/mm 3 ) and adjusted for updated age, plasma HIV-1 RNA, AIDS status, ARV treatment and primary prophylaxis, as well as for sex and transmission group. The adjusted incidence rates (IRs) for events in the two groups were derived from the Poisson regression models. All statistical analyses were performed using the SAS software package version 9.1 (SAS Institute, Cary, NC, USA).
Results
During the study period, 953 patients received at least one injection of IL-2. They were matched with 27750 unexposed patients, corresponding to a median of 30 [interquartile range (IQR), [29] [30] unexposed patients per exposed patient. Follow-up totalled 3447 and 95 800 person-years (PY), respectively.
At baseline, 21.7% of the patients in the IL-2-treated group were female, median age was 42.0 years (IQR, 36.2 -48.3), Fontas et al. Unless otherwise indicated. c Patients receiving primary prophylaxis for pneumocystosis and/or toxoplasmosis (co-trimoxazole, dapsone, pyrimethamine, atovaquone, pentamidine). Fontas et al. 38 .8% of the patients had AIDS and 88.0% were receiving cART. The CD4 cell count was below 200 cells/mm 3 in 43.6% of cases and the plasma HIV-1 RNA level was below 500 copies/mL in 77.3% of cases. Median follow-up was 45.7 months (IQR, 19.9-64.4), and 85.1% of these patients received their first injection of IL-2 after August 1999, when an expanded access programme was implemented.
In the IL-2-untreated group, 21.5% of patients were female, median age was 41.1 years (IQR, 36.2 -47.9), 35.0% of the patients had AIDS and 83.3% were receiving cART. The CD4 cell count was below 200 cells/mm 3 in 42.9% of cases and the plasma HIV-1 RNA level was below 500 copies/mL in 77.3% of cases. Median follow-up was 41.5 months (IQR, 18.3-61.0).
The clinical and epidemiological characteristics of the study population according to the baseline CD4 cell count (, or ≥200 cells/mm 3 ) are shown in Tables 1 and 2 . The exposed and unexposed populations were comparable with respect to their baseline characteristics.
Incidence and nature of events
Eighty IL-2-treated patients experienced clinical progression [23. 4 cases per 1000 PY (95% CI, 22.3-24.5)] after a median of 23.1 (IQR, 6.0 -36.3) months. Of these, 46 patients had an ADE and 34 patients died without having had an ADE. The most common ADEs were tuberculosis (n¼ 6), CMV disease (n¼ 5) and toxoplasmosis, HIV encephalopathy and recurrent bacterial pneumonia (4 cases each).
In the IL-2-untreated group, 2945 patients experienced clinical progression [31.1 cases per 1000 PY (95% CI, 30.0 -32.2)], after a median of 17.7 (IQR, 7.1-36.3) months. Of these, 1752 patients had an ADE and 1193 patients died without having had an ADE. The most frequent ADEs were oesophageal or pulmonary candidiasis, tuberculosis and Pneumocystis carinii pneumonia (285, 247 and 156 cases, respectively).
Changes in CD4 cell count
As expected, the CD4 cell count increase was significantly higher in the IL-2-treated group (Table 3) . With the exception of the ,50 cells/mm 3 stratum, the CD4 cell count increments in the individual baseline strata were all larger in the exposed group than in the unexposed group.
Clinical progression according to CD4 cell count at IL-2 treatment initiation
As shown in Table 4 , a clinical benefit of IL-2 therapy was noted in patients who started IL-2 therapy with CD4 cell counts ,200 cells/mm 3 but not in patients with higher counts. Of note, the HR was the same in the CD4 cell count strata ,50, 50 to ,100 and 100 to ,200 cells/mm 3 for an overall ratio of 0.64 (P ¼0.0027). The Cox model showed an overall clinical benefit in patients who started IL-2 therapy with a CD4 cell count below 200 cells/mm 3 . After adjustment for known risk factors for ADEs and death, the relative rate (RR) of clinical progression in IL-2-treated versus IL-2-untreated patients was 0.83 (95% CI, 0.42 -1.67, P ¼ 0.6073) among patients whose updated CD4 cell counts remained below 100 cells/mm 3 and 1.02 (95% CI, 0.14-7.22, P ¼ 0.9856) among patients whose CD4 cell counts increased above 350 cells/mm 3 (Table 5 ). However, IL-2-treated patients with updated CD4 cell counts in the 100 to ,350 cells/mm 3 stratum had a 70% lower risk of ADEs or death compared with IL-2-untreated patients (RR¼ 0.30; 95% CI, 0.09 -1.03, P ¼ 0.0548). Incidence rates of ADEs or death in the IL-2-treated and IL-2-untreated populations with ,200 CD4 cells/mm 3 at baseline are shown in Figure 1 according to updated CD4 cell counts.
Discussion
In this large exposed-unexposed observational cohort study of HIV-1-infected patients, we used a composite clinical endpoint to investigate whether the CD4 cell count level at initiation of IL-2 could influence the clinical benefit as a way to explain why the observed increase in the CD4 cell count induced by IL-2 therapy did not translate into a clinical benefit as shown in the ESPRIT and SILCAAT trials. Our main finding is that no clinical benefit occurs among patients who have CD4 cell counts above 200 cells/mm 3 when IL-2 therapy begins, while patients with baseline counts below 200 cells/mm 3 have a significant reduction in the risk of ADEs and death (HR¼ 0.64; 95% CI, 0.48-0.86). This result was explained by the time spent during follow-up in the 100 to ,350 cells/mm 3 CD4 cell count stratum, in which the relative rate of progression was 0.30 (95% CI, 0.09-1.03), while no such effect was observed in the strata below 100 cells/mm 3 (RR ¼0.83; 95% CI, 0.44 -1.57) or above 350 cells/mm 3 (RR ¼1.01; 95% CI, 0.17-6.18). As IL-2 therapy was not randomly assigned in our cohort, we used an exposed/unexposed matched design to ensure that the two populations were comparable at baseline. Furthermore, patients in the exposed group who had CD4 cell counts over 200 cells/mm 3 at baseline received IL-2 therapy as part of randomized trials, 24 further minimizing the risk of an indication bias. Patients who had CD4 cell counts below 200 cells/mm 3 at baseline received IL-2 therapy mainly through an expanded access programme. An indication bias in this subpopulation would probably have increased the risk of clinical progression, whereas we found a clinical benefit of IL-2. Patients who receive IL-2 as part of the expanded access programme might be expected to be more adherent to cART than patients who do not receive IL-2, and we therefore adjusted our analyses for plasma HIV-1 RNA load, which is largely dependent on adherence. To explore the possible misclassification of IL-2-exposed and -unexposed patients, we audited the 'IL-2 exposure' variable in a subset of exposed patients. According to the medical records, only 23 of the 598 patients were incorrectly classified as having received IL-2. Likewise, it is possible that some exposed patients were incorrectly classified as not having received IL-2 but, given the very large size of the unexposed population, this would have had a marginal impact on our findings. We did not investigate the possible dose -effect relationship between IL-2 therapy and the risk of clinical progression, as the doses used and the number of injections are not routinely recorded in the FHDH.
Our results are in keeping with those of the ESPRIT trial, which showed no benefit of IL-2 in patients with baseline CD4 cell counts above 300 cells/mm 3 . In contrast, we found evidence that IL-2 therapy may be deleterious in such patients (IQR, . The proportion of the study period spent with counts above 350 cells/mm 3 was 38% and 28%, respectively, in the IL-2-treated and -untreated groups of the SILCAAT trial, compared with 19% in both our groups. The proportion of the study period spent with counts below 200/mm 3 was 23% and 29%, respectively, in the IL-2-treated and untreated groups of the SILCAAT trial, compared with 45% and 47%, respectively, in our study. It can be suggested that by studying a population with higher CD4 cell counts at enrolment and shorter follow-up with low to intermediate CD4 cell counts, the SILCAAT investigators were unable to detect the potential clinical benefit that we observed in the 100 to ,350 cells/mm 3 CD4 cell count stratum during follow-up. Our data are also supported by the observation that IL-2 expands different populations of regulatory T cells (Treg), 25 the magnitude of the expansion depending on the baseline CD4 count. IL-2-induced Treg may not participate in host defences in HIV patients or may even hinder the generation of effector responses against pathogens. Together, these data suggest that the clinical outcome of IL-2-treated patients is critically dependent on the balance between IL-2-expanded Treg and effector T cells.
In conclusion, our findings in an observational setting suggest that any clinical benefit of IL-2 therapy could be restricted to a narrow range of CD4 cell counts, thus undermining the rationale for its use in HIV infection with the objective of diminishing the occurrence of clinical events. Immunotherapies that could provide the same clinical benefit observed in patients with low to intermediate CD4 cell counts without having the negative effects on outcome noted in patients with higher counts could be of interest to the many patients in whom HIV infection is diagnosed late, when the CD4 cell count is already below 200/mm 3 or AIDS has occurred, 26 or to cART-receiving patients whose CD4 cell counts do not increase. Intermittent IL-7 therapy, which is better tolerated than IL-2, shows promise in this setting, and the results of large trials with clinical endpoints are eagerly awaited. 27 Other approaches include the use of maraviroc, a CCR5 antagonist that bolsters the effect of cART on the CD4 cell count. 
